文献速递结核与非结核分枝杆菌艾滋病与性传播感染

结核治疗结局相关CD4+T细胞标志物:阿司匹林与布洛芬辅助治疗IIB期试验亚组分析

CD4+ T cell markers associated with Treatment Outcomes in Tuberculosis: A Sub-analysis of a Phase IIB Trial of Acetylsalicylic acid and Ibuprofen as Adjunctive Therapy.
PubMed 文献 · J Infect Dis · 2026-07-29

该研究为SMA-TB临床试验的亚组分析,纳入72例药物敏感肺结核患者(35.2%合并HIV),评估辅助阿司匹林或布洛芬治疗对结核结局的影响,并分析CD4+T细胞亚群作为预测标志物。结果显示,无论干预或HIV共感染,多数患者第24周痰培养快速转阴且临床和影像学结局良好;未发现阿司匹林或布洛芬组与安慰剂组在任何结局上有统计学显著差异。基线多功能及CD153表达CD4+T细胞比例较高与阿司匹林组和安慰剂组痰培养快速转阴相关。

要点

  • 辅助阿司匹林或布洛芬未显著改善结核治疗结局,不支持常规使用。
  • 基线多功能及CD153+ CD4+T细胞比例高与痰培养快速转阴相关。
  • CD4+T细胞亚群有望作为结核疾病严重程度和结局预测标志物。

核心结论

  • CD4+T细胞亚群有潜力作为结核疾病严重程度及微生物学、临床和影像学结局的预测标志物。
  • 现有证据不足以支持常规使用阿司匹林或布洛芬作为辅助宿主导向治疗。

研究设计与样本

  • SMA-TB临床试验的亚组分析,纳入72例南非药物敏感肺结核患者,其中35.2%合并HIV。
  • 采用流式细胞术在基线、第2周、第8周和第24周分析CD4+T细胞亚群及Mtb特异性CD4+T细胞反应。

主要发现

  • 多数患者在第24周实现快速痰培养转阴,临床和影像学结局良好,与干预措施或HIV共感染无关。
  • 治疗期间Mtb特异性多功能CD4+T细胞、Th1和Th1/Th17亚群比例及CD153表达增加,Ki67+HLA-DR+ CD4+T细胞下降。
  • 阿司匹林或布洛芬组与安慰剂组在任何定义结局上均无统计学显著差异。
  • 基线多功能及CD153表达CD4+T细胞比例较高与阿司匹林组和安慰剂组痰培养快速转阴相关。

临床怎么用

  • 目前不推荐常规使用阿司匹林或布洛芬作为结核辅助宿主导向治疗。
  • CD4+T细胞亚群(如多功能、CD153表达)可作为潜在生物标志物用于结核结局预测,但需进一步验证。

局限性

  • 本研究为亚组分析,样本量有限,结果需更大规模靶向研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjunctive host-directed therapies (HDT) may improve treatment outcomes in tuberculosis (TB). Affordable repurposed drugs can be quickly implemented in clinical practice; however, predictive biomarkers are essential for determining their potential effectiveness. METHODS: 72 patients (35.2% people with HIV) from South Africa with drug-sensitive pulmonary TB, recruited to the SMA-TB clinical trial of adjunctive acetylsalicylic acid (ASA) and ibuprofen (IBU), were included. CD4+ T cell subsets and Mtb-specific CD4+ T cell responses were analysed by flow cytometry at baseline, week 2, week 8 and week 24 and tested as predictors for microbiological, clinical and radiological outcomes. RESULTS: Most TB patients experienced a fast sputum culture conversion and good clinical and radiological outcomes by week 24, regardless of intervention or HIV co-infection. During TB therapy, fractions of Mtb-specific polyfunctional CD4+ T cells, Th1 and Th1/Th17 subsets, and CD153 expression increased, whereas Ki67+HLA-DR+ CD4+ T cells declined. No statistically significant differences were identified between the ASA or IBU groups and placebo for any defined outcome. Still, higher baseline fractions of polyfunctional and CD153-expressing CD4+ T cells were associated with fast sputum culture conversion in the ASA and placebo arms. CONCLUSIONS: CD4+ T cell subsets show promise as markers of disease severity and potential predictors of microbiological, clinical, and radiological outcomes in treated TB. However, the present findings are insufficient to support the routine use of ASA or IBU in adjunctive HDT regimens, and larger, targeted studies are warranted.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Alonso-Rodríguez N, Edlund IH, Aass HCD, et al. CD4+ T cell markers associated with Treatment Outcomes in Tuberculosis: A Sub-analysis of a Phase IIB Trial of Acetylsalicylic acid and Ibuprofen as Adjunctive Therapy. J Infect Dis. 2026. PMID: 42522698. doi:10.1093/infdis/jiag380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。